Crossmark

Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study

Crossref DOI link: https://doi.org/10.1186/s13075-019-1873-3

Published Online: 2019-04-05

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Moreno, Mireia

Gratacós, Jordi

Torrente-Segarra, Vicenç

Sanmarti, Raimon

Morlà, Rosa

Pontes, Caridad

Llop, Maria

Juanola, Xavier
Funding

Funding for this research was provided by:

MSD K.K.
License Information

Text and Data Mining valid from 2019-04-05
More Information

Article History

Received: 27 November 2018

Accepted: 22 March 2019

First Online: 5 April 2019

Ethics approval and consent to participate

: All patients included signed an informed consent to participate in REMINEA and the project was approved by ethical committee of all participant hospitals.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.